bevacizumab + encorafenib

bevacizumab + encorafenib is an investigational combination therapy consisting of a humanized monoclonal antibody and a small-molecule kinase inhibitor. Bevacizumab is an angiogenesis inhibitor that targets vascular endothelial growth factor A (VEGF-A), preventing its binding to receptors on the surface of endothelial cells, which inhibits the growth of new blood vessels that supply tumors. Encorafenib is a potent and selective inhibitor of the BRAF kinase, specifically targeting the V600E mutation commonly found in metastatic colorectal cancer (mCRC). By simultaneously inhibiting the MAPK/ERK signaling pathway (via encorafenib) and the VEGF-mediated angiogenic pathway (via bevacizumab), the combination aims to overcome resistance and enhance antitumor activity. This combination has been associated with clinical research at the Vall d'Hebron Institute of Oncology (VHIO) for the treatment of patients with BRAF-mutant mCRC, often explored in the context of rechallenge strategies for patients who have progressed on prior BRAF-inhibitor-based therapies.

Other names

bevacizumab and encorafenibencorafenib plus bevacizumab